US FDA finally approves GSK's Promacta
This article was originally published in Scrip
Executive Summary
The US FDAhas finally approved GlaxoSmithKline's novel treatment for thrombocytopenia, Promacta (eltrombopag). The approval makes it the first oral thrombopoietin receptor agonist to be approved, and comes after the agency missed its September user fee deadline, which had already been pushed back from June.